openPR Logo
Press release

One "Target" for a Month: Creative Biolabs Features TNFRSF9

07-10-2024 08:20 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Getnews

/ PR Agency: PRChoices
One "Target" for a Month: Creative Biolabs Features TNFRSF9

Creative Biolabs introduces its range of TNFRSF9-related antibody reagents.
New York, USA - July 10, 2024 - The growing interest in TNFRSF9 (also known as CD137, 4-1BB) stems from its role as a co-stimulatory receptor on T cells, which can enhance immune responses against tumors. Research has shown that activating TNFRSF9 can significantly boost the efficacy of cancer immunotherapies. To synchronize with recent industry news highlighting the potential of TNFRSF9-targeted therapies to overcome the limitations of existing treatments and deliver durable anti-tumor responses, Creative Biolabs specifies their anti-TNFRSF9 engineered antibodies [https://www.creativebiolabs.net/symbolsearch_TNFRSF9_2.htm] in the monthly briefing.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

I: Leading in with the Omnipresent Hi-Affi Trademark

"First of all, a short overview of our Hi-Affi Trademark platform to get you a clearer picture of our antibody performance," according to the scientist delivering the presentation, "which is a concert of advanced DNA technologies and powerful cell-free expression systems."

Almost all production work of recombinant antibodies [https://www.creativebiolabs.net/hi-affi-tm-recombinant-antibodies.htm] is run by the Hi-Affi Trademark platform, covering antibodies of different working modalities (blocking, neutralizing, etc.), antibodies against divergent targets (epitope-specific, mRNA encoded, etc.), and antibodies originated from different species (chicken, rabbit, etc.), with which the yielding reagents will be validated to have over 98% purity, high affinity, and reproducibility.

II: Catalog presentation

The scientist revealed a list of their research-use-only antibodies that are readily available for global delivery, and announced that the list is growing to cover more isotypes and more validated applications.

* Rat Anti-TNFRSF9 Recombinant Antibody

* Recombinant Mouse Anti-Human TNFRSF9 Antibody

* Hamster Anti-TNFRSF9 Recombinant Antibody

* Rat Anti-TNFRSF9 Recombinant Antibody

* Rat Anti-TNFRSF9 Recombinant Antibody

* Human Anti-TNFRSF9 Recombinant Antibody

* Human Anti-TNFRSF9 Recombinant Antibody

III: Case study: urelumab-a therapeutic breakthrough

Furthermore, a candidate that had received its final clinical results not a while ago was discussed-urelumab, an agonistic antibody targeting 4-1BB, making it a valuable tool in the fight against cancer. Two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors were reported in the paper.

"For relevant studies, we have anti-human 4-1BB recombinant antibodies [https://www.creativebiolabs.net/Anti-Human-4-1BB-Therapeutic-Antibody-Urelumab-13548.htm]," the scientist added, "which have been validated to be positive against native human antigen. Tested data are provided on the product page to help researchers know more about how they work in specific assays, like WB and ELISA."

IV: Outlook

Creative Biolabs prides itself on its commitment to innovation and collaboration and is poised to play a pivotal role in advancing TNFRSF9-targeted therapies.

"As the research community continues to explore the full potential of such critical factors in immunotherapy, we remain dedicated to driving scientific progress." The scientist summarized.

For more information about Creative Biolabs' TNFRSF9 antibodies and to explore their comprehensive product offerings, visit https://www.creativebiolabs.net or contact their expert team.

Company Overview

Creative Biolabs is a biotechnology company specializing in antibody development, engineering, and production. With a strong focus on innovation and customer service, Creative Biolabs provides a wide range of high-quality antibody products to support biomedical research and drug development worldwide.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email [http://www.universalpressrelease.com/?pr=one-target-for-a-month-creative-biolabs-features-tnfrsf9]
Phone: 1-631-830-6441
Country: United States
Website: https://www.creativebiolabs.net



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release One "Target" for a Month: Creative Biolabs Features TNFRSF9 here

News-ID: 3575212 • Views:

More Releases from Getnews

Experience Seamless Crypto Spending with Giveaway.com's New PennyWin Feature
Experience Seamless Crypto Spending with Giveaway.com's New PennyWin Feature
Giveaway.com introduces PennyWin, a new feature aimed at enhancing the interaction with digital currencies. This addition is designed to make the use of cryptocurrencies more integral to daily financial activities, transitioning them from primarily trading commodities to versatile, everyday financial tools. With PennyWin, users can earn, play, and spend digital currencies, integrating them into everyday financial transactions. This feature seeks to normalize digital spending, making it as commonplace as using
China aims to elevate BRI cooperation toward higher quality for modernization of all countries
China aims to elevate BRI cooperation toward higher quality for modernization of …
China has signed BRI cooperation documents with over 150 countries and over 30 international organizations, and last year, China's trade with partner countries reached 19.5 trillion yuan (about 2.74 trillion U.S. dollars), up by 2.8 percent, accounting for 46.6 percent of the total import and export volume, setting a new record both for the size and share since the BRI was put forward. BEIJING - July 22, 2024 - China
How to Dodge the Pitfalls in Cell Therapy R&D? Creative Biolabs Navigates a Pathway From Theory to Practice
How to Dodge the Pitfalls in Cell Therapy R&D? Creative Biolabs Navigates a Path …
A scientist from Creative Biolabs presents the routes they use to manage the development of novel CAR-T, TCR-T, and scFv-TCR T cell therapies. New York, USA - July 22, 2024 - CAR-T cell therapy, having revolutionized the treatment of many intractable diseases, particularly cancer, critically influences the entire landscape of medical advancements. Creative Biolabs supports any projects involved in the area with its customized CAR-T cell [https://www.creative-biolabs.com/car-t/one-stop-car-t-therapy-development-services.htm] therapy development solution, which
Addictive Tips Reveals the Top 5 Fastest VPNs of 2024
Addictive Tips Reveals the Top 5 Fastest VPNs of 2024
Addictive Tips unveils the Top 5 Fastest VPNs of 2024, emphasizing the importance of speed for streaming, gaming, and remote work. Technology expert Geoffrey Walters provides an in-depth analysis, helping users make informed decisions while benefiting from exclusive deals and offers. Image: https://www.getnews.info/uploads/1aecd1578f4cf1c5d5e1cdb7514f9f9e.jpg In a world where online security and anonymity becomes increasingly important, gamers are making use of Virtual Private Networks (VPNs) for added security. At its core, VPNs encrypts and

All 5 Releases


More Releases for TNFRSF9

Tumor Necrosis Factor Receptor Superfamily Member 9: North America to Retain its …
Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) pipeline Target constitutes close to 35 molecules. Out of which approximately 31 molecules are developed by companies and remaining by the universities/institutes. To evaluate factors influencing Tumor Necrosis Factor Receptor Superfamily Member 9, Market Research Hub (MRH) has included a report titled “Tumor Necrosis Factor Receptor
Tumor Necrosis Factor Receptor Superfamily Member 9 -Pipeline Review, H2 2017
"The Report Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" According to the recently published report Tumor Necrosis Factor Receptor Superfamily Member 9-Pipeline Review, H2 2017; Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB